Alder BioPharmaceuticals Inc. (NASDAQ:ALDR)’s share price shot up 4.3% on Friday . The company traded as high as $26.99 and last traded at $26.67, with a volume of 499,387 shares. The stock had previously closed at $25.56.

A number of brokerages have recently weighed in on ALDR. Jefferies Group reiterated a “buy” rating and set a $61.00 target price on shares of Alder BioPharmaceuticals in a research note on Thursday, June 9th. Zacks Investment Research upgraded Alder BioPharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, May 30th. Wells Fargo & Co. began coverage on Alder BioPharmaceuticals in a research note on Thursday, April 21st. They set an “outperform” rating on the stock. Brean Capital began coverage on Alder BioPharmaceuticals in a research note on Wednesday, April 20th. They set a “buy” rating and a $45.00 target price on the stock. Finally, Leerink Swann reiterated an “outperform” rating on shares of Alder BioPharmaceuticals in a research note on Tuesday, March 29th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Alder BioPharmaceuticals currently has an average rating of “Buy” and a consensus target price of $52.00.

The company’s market cap is $1.32 billion. The company has a 50-day moving average price of $27.44 and a 200-day moving average price of $25.47.

Alder BioPharmaceuticals (NASDAQ:ALDR) last issued its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by $0.04. During the same period in the previous year, the company earned ($0.40) earnings per share. Equities research analysts forecast that Alder BioPharmaceuticals Inc. will post ($3.25) earnings per share for the current year.

In other news, VP Jeffrey T. L. Smith sold 16,090 shares of the business’s stock in a transaction that occurred on Friday, June 3rd. The stock was sold at an average price of $30.20, for a total value of $485,918.00. Following the transaction, the vice president now owns 16,090 shares in the company, valued at approximately $485,918. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mark James Litton sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $28.94, for a total value of $173,640.00. Following the completion of the transaction, the insider now owns 74,567 shares in the company, valued at approximately $2,157,968.98. The disclosure for this sale can be found here.

Several institutional investors have made changes to their positions in the company. Pyrrho Capital Management LP increased its position in shares of Alder BioPharmaceuticals by 205.0% in the fourth quarter. Pyrrho Capital Management LP now owns 63,000 shares of the biopharmaceutical company’s stock worth $2,081,000 after buying an additional 42,343 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Alder BioPharmaceuticals by 290.6% in the fourth quarter. Wells Fargo & Company MN now owns 269,774 shares of the biopharmaceutical company’s stock worth $8,911,000 after buying an additional 200,707 shares during the last quarter. Brown Advisory Inc. increased its position in shares of Alder BioPharmaceuticals by 118.8% in the fourth quarter. Brown Advisory Inc. now owns 379,579 shares of the biopharmaceutical company’s stock worth $12,538,000 after buying an additional 206,108 shares during the last quarter. ProShare Advisors LLC increased its position in shares of Alder BioPharmaceuticals by 8.6% in the fourth quarter. ProShare Advisors LLC now owns 38,476 shares of the biopharmaceutical company’s stock worth $1,271,000 after buying an additional 3,058 shares during the last quarter. Finally, California Public Employees Retirement System increased its position in shares of Alder BioPharmaceuticals by 834.5% in the fourth quarter. California Public Employees Retirement System now owns 81,300 shares of the biopharmaceutical company’s stock worth $2,685,000 after buying an additional 72,600 shares during the last quarter.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.